Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials

PURPOSE: COVID-19 is characterized by dysregulated immune response, respiratory failure and a relevant mortality rate among hospitalized patients. Interleukin-6 (IL-6) is involved in COVID-19-associated cytokine storm, and several trials investigated whether its inhibition could improve patients’ ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Belletti, Alessandro, Campochiaro, Corrado, Marmiere, Marilena, Likhvantsev, Valery, Yavorovskiy, Andrey, Dagna, Lorenzo, Landoni, Giovanni, Zangrillo, Alberto, Hajjar, Ludhmila Abrahão
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547720/
https://www.ncbi.nlm.nih.gov/pubmed/34704175
http://dx.doi.org/10.1186/s13613-021-00941-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547720/
https://www.ncbi.nlm.nih.gov/pubmed/34704175
http://dx.doi.org/10.1186/s13613-021-00941-2

Ejemplares similares